Literature DB >> 16574944

Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice.

Roderick J Tan1, Cheryl L Fattman, Laura M Niehouse, Jacob M Tobolewski, Lana E Hanford, Qinglang Li, Federico A Monzon, William C Parks, Tim D Oury.   

Abstract

Inhalation of asbestos fibers causes pulmonary inflammation and eventual pulmonary fibrosis (asbestosis). Although the underlying molecular events are poorly understood, protease/antiprotease and oxidant/antioxidant imbalances are believed to contribute to the disease. Implicated in other forms of pulmonary fibrosis, the matrix metalloproteinases (MMPs) have not been examined in asbestosis. We therefore hypothesized that MMPs play a pathogenic role in asbestosis development. Wild-type C57BL/6 mice were intratracheally instilled with 0.1 mg crocidolite asbestos, causing an inflammatory response at 1 d and a developing fibrotic response at 7, 14, and 28 d. Gelatin zymography demonstrated an increase in MMP-9 (gelatinase B) during the inflammatory phase, while MMP-2 (gelatinase A) was profoundly increased in the fibrotic phase. Immunohistochemistry revealed MMP-9 in and around bronchiolar and airspace neutrophils that were often associated with visible asbestos fibers. MMP-2 was found in fibrotic regions at 7, 14, and 28 d. No increases in RNA levels of MMP-2, MMP-9, or MMP-8 were found, but levels of MMP-7, MMP-12, and MMP-13 RNA did increase at 14 d. The MMP inhibitors, TIMP-1 and TIMP-2, were also increased at 7-28 d after asbestos exposure. To confirm the importance of MMP activity in disease progression, mice exposed to asbestos were given daily injections of the MMP inhibitor, GM6001. MMP inhibition reduced inflammation and fibrosis in asbestos-treated mice. Collectively, these data suggest that MMPs contribute to the pathogenesis of asbestosis through effects on inflammation and fibrosis development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574944      PMCID: PMC1820635          DOI: 10.1165/rcmb.2005-0471OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  38 in total

1.  TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?

Authors:  M Selman; V Ruiz; S Cabrera; L Segura; R Ramírez; R Barrios; A Pardo
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-09       Impact factor: 5.464

2.  Gelatinase B is required for alveolar bronchiolization after intratracheal bleomycin.

Authors:  T Betsuyaku; Y Fukuda; W C Parks; J M Shipley; R M Senior
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Domain interactions in the gelatinase A.TIMP-2.MT1-MMP activation complex. The ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation.

Authors:  C M Overall; E Tam; G A McQuibban; C Morrison; U M Wallon; H F Bigg; A E King; C R Roberts
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

Review 4.  Oxidant and antioxidant mechanisms of lung disease caused by asbestos fibres.

Authors:  V L Kinnula
Journal:  Eur Respir J       Date:  1999-09       Impact factor: 16.671

5.  Increased sensitivity to asbestos-induced lung injury in mice lacking extracellular superoxide dismutase.

Authors:  Cheryl L Fattman; Roderick J Tan; Jacob M Tobolewski; Tim D Oury
Journal:  Free Radic Biol Med       Date:  2005-10-19       Impact factor: 7.376

6.  The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.

Authors:  C M Swaisgood; E L French; C Noga; R H Simon; V A Ploplis
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

7.  Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias.

Authors:  M Suga; K Iyonaga; T Okamoto; Y Gushima; H Miyakawa; T Akaike; M Ando
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

8.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3.

Authors:  G A McQuibban; J H Gong; E M Tam; C A McCulloch; I Clark-Lewis; C M Overall
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

9.  Tissue inhibitor of metalloproteinase-1 deficiency amplifies acute lung injury in bleomycin-exposed mice.

Authors:  Kyoung-Hee Kim; Kristin Burkhart; Peter Chen; Charles W Frevert; Julie Randolph-Habecker; Robert C Hackman; Paul D Soloway; David K Madtes
Journal:  Am J Respir Cell Mol Biol       Date:  2005-06-09       Impact factor: 6.914

Review 10.  Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy.

Authors:  Vuokko L Kinnula; Cheryl L Fattman; Roderick J Tan; Tim D Oury
Journal:  Am J Respir Crit Care Med       Date:  2005-05-13       Impact factor: 21.405

View more
  47 in total

1.  Rapid determination of enzyme kinetics from fluorescence: overcoming the inner filter effect.

Authors:  Mark O Palmier; Steven R Van Doren
Journal:  Anal Biochem       Date:  2007-07-18       Impact factor: 3.365

2.  Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury.

Authors:  Daniel J Kass; Guoying Yu; Katrina S Loh; Asaf Savir; Alain Borczuk; Rehan Kahloon; Brenda Juan-Guardela; Giuseppe Deiuliis; John Tedrow; Jiin Choi; Thomas Richards; Naftali Kaminski; Steven M Greenberg
Journal:  Am J Pathol       Date:  2012-03-16       Impact factor: 4.307

3.  Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.

Authors:  Elliot L Servais; Christos Colovos; Luis Rodriguez; Adam J Bograd; Jun-ichi Nitadori; Camelia Sima; Valerie W Rusch; Michel Sadelain; Prasad S Adusumilli
Journal:  Clin Cancer Res       Date:  2012-02-27       Impact factor: 12.531

Review 4.  Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?

Authors:  Derek C Radisky; Paraic A Kenny; Mina J Bissell
Journal:  J Cell Biochem       Date:  2007-07-01       Impact factor: 4.429

5.  Differential expression of MMP-2 and -9 and their inhibitors in fetal lung cells exposed to mechanical stretch: regulation by IL-10.

Authors:  Renda L Hawwa; Michael A Hokenson; Yulian Wang; Zheping Huang; Surendra Sharma; Juan Sanchez-Esteban
Journal:  Lung       Date:  2011-06-24       Impact factor: 2.584

6.  Diospyros blancoi attenuates asthmatic effects in a mouse model of airway inflammation.

Authors:  Kyoung-Youl Lee; Ju-Young Jung; Mee-Young Lee; Dayoung Jung; Eun-Sang Cho; Hwa-Young Son
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

7.  Response of the mouse lung transcriptome to welding fume: effects of stainless and mild steel fumes on lung gene expression in A/J and C57BL/6J mice.

Authors:  Patti C Zeidler-Erdely; Michael L Kashon; Shengqiao Li; James M Antonini
Journal:  Respir Res       Date:  2010-06-03

8.  The role of the receptor for advanced glycation end-products in a murine model of silicosis.

Authors:  Lasse Ramsgaard; Judson M Englert; Jacob Tobolewski; Lauren Tomai; Cheryl L Fattman; Adriana S Leme; A Murat Kaynar; Steven D Shapiro; Jan J Enghild; Tim D Oury
Journal:  PLoS One       Date:  2010-03-19       Impact factor: 3.240

9.  Vitamin E deficiency enhances pulmonary inflammatory response and oxidative stress induced by single-walled carbon nanotubes in C57BL/6 mice.

Authors:  Anna A Shvedova; Elena R Kisin; Ashley R Murray; Olga Gorelik; Sivaram Arepalli; Vincent Castranova; Shih-Hong Young; Fei Gao; Yulia Y Tyurina; Tim D Oury; Valerian E Kagan
Journal:  Toxicol Appl Pharmacol       Date:  2007-03-27       Impact factor: 4.219

10.  Lung inflammation, injury, and proliferative response after repetitive particulate hexavalent chromium exposure.

Authors:  Laura M Beaver; Erik J Stemmy; Arnold M Schwartz; Jesse M Damsker; Stephanie L Constant; Susan M Ceryak; Steven R Patierno
Journal:  Environ Health Perspect       Date:  2009-08-19       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.